GTX TO INITIATE TRIAL OF DRUG FOR MUSCLE AND BONE GROWTH

GTx announced completion of recruitment of its proof-of-concept Phase II trial of ostarine, a selective androgen receptor modulator (SARM). GTx expects to report data from the trial in the fourth quarter.

The three-month placebo-controlled trial is evaluating multiple doses of ostarine in 60 older men and 60 postmenopausal women. The trial is designed to evaluate the activity of ostarine on building muscle and promoting bone growth, as well as to assess safety in both older men and postmenopausal women. Based on ostarine's Phase II clinical data profile, GTx will select specific acute and chronic bone and/or muscle wasting diseases for further development.